Blood:血小板反应蛋白-1通过调节血小板的cAMP信号促进止血

2020-09-15 MedSci原创 MedSci原创

血小板激活后,释放的血小板反应蛋白(TSP-1)增加,又可促进血小板激活,但其在体内止血中的作用尚不明确。

血小板激活后,释放的血小板反应蛋白(TSP-1)增加,又可促进血小板激活,但其在体内止血中的作用尚不明确。

Aburima等人发现TSP-1是止血的重要介导因子,可通过抑制cAMP促进血小板激活。在体外,敲除TSP-1基因不影响血小板的激活,但在止血和血栓形成的模型体内,TSP-1缺陷可延长小鼠的出血时间,导致血栓形成缺陷和对前列环素模拟物伊洛前列素的敏感性增强。移植野生型(WT)小鼠的血小板可改善血栓表型,但移植TSP-1-/-型血小板则不能,提示血小板来源的TSP-1有重要的功能。

在功能分析实验中,TSP-1缺陷型血小板对cAMP信号、PGI2对血流中血小板聚集和阻滞抑制的敏感性增强。血浆置换实验显示,血浆TSP-1不能纠正TSP-1-/-型血小板的PGI2高敏感性。

相反,将TSP-1-/-型血小板与WT型血小板的释放物或纯化的TSP-1一起孵育,可减弱PGI2的抑制作用,但与TSP-1-/-型血小板的释放物一起孵育无此效应。WT型血小板激活可减少cAMP积累和下游信号,与cAMP水解酶磷酸二酯酶3A(PDE3A)的活性增加有关。TSP-1-/-小鼠血小板的PDE3A活性和cAMP积累未受影响。TSP-1受体CD36缺陷的血小板对PGI2/cAMP信号的敏感性增强,PDE3A活性减弱,且不受血小板来源的或纯化的TSP-1的影响。

本研究结果表明,TSP-1的释放通过调节血管损伤部位的血小板cAMP信号调控体内止血。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2021-01-23 1477308bm10(暂无昵称)

    学习了 谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-12-27 whmdzju
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-17 jeanqiuqiu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 qinqiyun

    血小板

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1974070, encodeId=e51919e4070c6, content=<a href='/topic/show?id=5fd88902843' target=_blank style='color:#2F92EE;'>#血小板反应蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89028, encryptionId=5fd88902843, topicName=血小板反应蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sun Nov 08 06:33:42 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919283, encodeId=7c8a9192830c, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Sat Jan 23 20:52:37 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738432, encodeId=c0a41e3843231, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Sat Aug 21 23:33:42 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675362, encodeId=208216e5362c5, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Sun Dec 27 08:33:42 CST 2020, time=2020-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263092, encodeId=8271126309239, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Sep 17 12:33:42 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885906, encodeId=6a8788590699, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Sep 16 22:25:43 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885718, encodeId=d01b885e188e, content=血小板, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Wed Sep 16 10:50:41 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885662, encodeId=6660885662b9, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 16 08:18:39 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 14818eb4m67暂无昵称

    学习

    0

相关资讯

AJG:消化性溃疡出血患者内镜止血后的更佳喂养时间是什么时候

消化性溃疡出血患者内镜止血后的最佳进食时间尚未确定。本项研究旨在评估内镜止血后高危消化性溃疡出血患者的最合适的喂养时间。

Stroke:平扫CT血肿扩大征象者可否使用止血药物?

急性脑出血(ICH)发病最初几个小时内,高达38%的患者会发生血肿扩大。不过,鉴于大部分 ICH 患者并未发生血肿扩大,识别处于血肿扩大风险的患者是非常重要的,比如在止血治疗的临床试验中有利于选择最有可能从止血治疗中获益的目标患者。

Blood:止血通过释放和激活VEGFC刺激淋巴管生成

组织损伤后止血,然后伤口愈合是一个复杂的过程,在这个过程中,受损的细胞物质被移除,组织被修复。血管生成反应是伤口愈合的一个重要方面,包括新淋巴管的生成,免疫细胞、蛋白质和液体均通过淋巴管运输出伤口区域。止血反应可能与伤口愈合反应相联系的概念由来已久,但在体内证明这种联系并确定这两个过程相联系的特定分子机制是困难的。在本研究中,研究人员发现凝血酶和纤溶酶(止血和伤口愈合过程中产生的丝氨酸蛋白酶)可以

J Endod:氯化铝和电灼法在尖周外科手术中的比较:一项随机对照试验

这篇研究的目的是为了比较和评估2种在尖周外科手术时应用的止血方法以及它们基于患者和牙齿变量的相互关系。

Blood:功能异常的FIX可干扰正常的FIX发挥止血作用

IX因子(FIX)可与内皮细胞下基底膜的胶原IV (Col4)结合。在B型血友病中,FIX-Col4的结合可减少输注的FIX的血浆回收率,在止血过程中具有重要意义。在交联反应阴性(cross-reactive material negative, CRM-)的B型血友病小鼠模型中评估输注的BeneFix(FIXWT)的回收情况的研究表明Col4结合FIX的适合浓度为~405 nM(95% CI 3

咯血的治疗药物选用及注意事项

咯血是喉及喉以下呼吸道任何部位的出血,经口腔排出的一种临床症状,通常规定24h内咯血大于500mL(或1次咯血量100mL以上)为大量咯血,100-500mL为中等量咯血,小于100mL为小量咯血。其中支气管扩张、结核、肺曲霉菌病、坏死性肺炎、隐源性咯血和肺癌被认为是大咯血最常见的原因。